Table 1.
Association between APP immunohistochemical status and clinicopathological parameters in 117 breast carcinomas
| APP status | P‐value | ||
|---|---|---|---|
| + (n = 57) | − (n = 60) | ||
| Age† (years) | 55.3 ± 1.4 | 56.9 ± 1.6 | 0.46 |
| Menopausal status | |||
| Premenopausal | 19 (16%) | 21 (18%) | 0.85 |
| Postmenopausal | 38 (32%) | 39 (33%) | |
| Stage | |||
| I | 15 (13%) | 22 (19%) | 0.63 |
| II | 28 (24%) | 25 (21%) | |
| III | 10 (9%) | 8 (7%) | |
| IV | 4 (3%) | 5 (4%) | |
| Pathological T factor (pT) | |||
| pT1 | 22 (19%) | 26 (22%) | 0.60 |
| pT2–4 | 35 (30%) | 34 (29%) | |
| Lymph node metastasis | |||
| Positive | 29 (25%) | 24 (21%) | 0.24 |
| Negative | 28 (24%) | 36 (31%) | |
| Distant metastasis | |||
| Positive | 4 (3%) | 5 (4%) | 0.79 |
| Negative | 53 (45%) | 55 (47%) | |
| Histological grade | |||
| 1 (well) | 11 (9%) | 14 (12%) | 0.60 |
| 2 (moderate) | 26 (22%) | 30 (26%) | |
| 3 (poor) | 20 (17%) | 16 (14%) | |
| ER status | |||
| Positive | 45 (38%) | 39 (33%) | 0.09 |
| Negative | 12 (10%) | 21 (18%) | |
| PR status | |||
| Positive | 33 (28%) | 30 (26%) | 0.39 |
| Negative | 24 (21%) | 30 (26%) | |
| AR status | |||
| Positive | 47 (40%) | 38 (32%) | 0.02* |
| Negative | 10 (9%) | 22 (19%) | |
| AR LI† (%) | 39.3 ± 3.8 | 20.3 ± 2.4 | <0.0001* |
| HER2 status | |||
| Positive | 14 (12%) | 10 (9%) | 0.29 |
| Negative | 43 (37%) | 50 (43%) | |
| Ki‐67 LI† (%) | 21.8 ± 2.2 | 18.6 ± 2.1 | 0.29 |
| Intrinsic subtype‡ | |||
| Luminal A | 25 (21%) | 31 (26%) | 0.047* |
| Luminal B | 20 (17%) | 10 (9%) | |
| HER2 positive | 8 (7%) | 7 (6%) | |
| Triple negative | 4 (3%) | 12 (10%) | |
*P‐values less than 0.05 were considered significant. †Data are presented as mean ± SEM. All other values represent the number of cases and percentage. ‡Intrinsic subtype was defined according to the 2011 St Gallen surrogate definition.20 APP, amyloid precursor protein; AR, Androgen receptor; ER, estrogen receptor; PR, progesterone receptor.